<SEC-DOCUMENT>0001157523-16-006461.txt : 20160805
<SEC-HEADER>0001157523-16-006461.hdr.sgml : 20160805
<ACCEPTANCE-DATETIME>20160805090017
ACCESSION NUMBER:		0001157523-16-006461
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20160805
FILED AS OF DATE:		20160805
DATE AS OF CHANGE:		20160805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		161809234

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a51396686.htm
<DESCRIPTION>AURINIA PHARMACEUTICALS INC. 6-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2016 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p style="text-align: center">
      <br>
      <font style="font-size: 16pt; font-family: Times New Roman"><b>UNITED
      STATES</b></font><b><font style="font-size: 16pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 16pt"></font><font style="font-size: 16pt; font-family: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Washington,
      D.C. 20549</b></font>
    </p>
    <hr style="text-align: center; color: #000000; height: 1.0 pt; width: 100%">


    <p style="text-align: center">
      <font style="font-size: 14pt; font-family: Times New Roman"><b>FORM 6-K</b></font>
    </p>
    <hr style="text-align: center; color: #000000; height: 1.0 pt; width: 100%">


    <p style="text-align: center">
      <font style="font-family: Times New Roman"><b>&#160;</b></font><b><font style="font-size: 12pt; font-family: Times New Roman">REPORT
      OF FOREIGN PRIVATE ISSUER</font></b><br><font style="font-size: 12pt; font-family: Times New Roman"><b>PURSUANT
      TO RULE 13A-16 OR 15D-16 UNDER THE</b></font><br><font style="font-size: 12pt; font-family: Times New Roman"><b>SECURITIES
      EXCHANGE ACT OF 1934</b></font><br><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Dated</b></font><font style="font-size: 10pt; font-family: Times New Roman">
      </font><font style="font-size: 10pt; font-family: Times New Roman"><b>August
      5, 2016</b></font><br><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Commission
      File Number</b></font><b> 001-36421</b>
    </p>
    <hr style="text-align: center; color: #000000; height: 1.0 pt; width: 100%">


    <p style="text-align: center">
      <font style="font-size: 24pt"><b>AURINIA PHARMACEUTICALS INC.</b></font><br><b>(Exact
      name of Registrant as specified in its charter)</b><br><br>
    </p>
    <hr style="text-align: center; color: #000000; height: 1.0 pt; width: 100%">


    <p style="text-align: center">
      <b>N/A</b><br><b>(Translation of Registrant&#8217;s Name)</b><br><br>
    </p>
    <p style="text-align: center">
      <b>#1203-4464 Markham Street</b><br><b>Victoria, British Columbia</b><br><b>V8Z7X8</b><br><b>(250)
      708-4272</b><br><b>(Address and telephone number of registrant&#8217;s
      principal executive offices)</b>
    </p>
    <p style="text-align: center">

    </p>
    <hr style="text-align: center; color: #000000; height: 1.0 pt; width: 100%">


    <p style="text-align: left; text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark whether the registrant files or will file annual reports
      under cover of Form 20-F or Form 40-F:</font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">Form 20-F &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><font style="font-size: 10pt; font-family: Times New Roman">
      &#160;&#160;&#160;&#160;Form 40-F&#160; </font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8864;</font>
    </p>
    <p style="text-align: left; text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(1):&#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><br>
    </p>
    <p style="text-align: left; text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(7):&#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><br>
    </p>
    <p style="text-align: justify; text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark whether by furnishing the information contained in this Form,
      the registrant is also thereby furnishing the information to the
      Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
      of 1934.</font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">Yes &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8864;</font><font style="font-size: 12pt">&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: Times New Roman">
      No &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font>
    </p>
    <p style="text-align: justify; text-indent: 30.0px">

    </p>
    <p style="margin-left: 30.0px; font-size: 10pt">
      &#160;&#160;&#160;This Form 6-K is hereby filed and incorporated by reference in the
      registrant&#8217;s Registration Statement on Form F-10 (File No. 333-206994).
    </p>
    <div style="width: 100%; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><br style="font-size: 10pt; font-family: Times New Roman">
      </font><font style="font-size: 10pt; font-family: Times New Roman"><b>SIGNATURES</b></font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized. </font>
    </p>
<div style="text-align:left">
    <table style="width: 100%; font-size: 10pt; font-family: Times New Roman; margin-bottom: 10.0px" cellspacing="0">
      <tr>
        <td style="width: 6%; padding-left: 0.0px; text-align: left" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Dated:
          </p>
        </td>
        <td style="width: 44%; padding-left: 0.0px; text-align: left" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            August 5, 2016
          </p>
        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td style="padding-left: 0.0px; text-align: left" colspan="3" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Aurinia Pharmaceuticals Inc.</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td style="padding-left: 0.0px; text-align: center" colspan="3" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%; padding-bottom: 2.0px; padding-left: 0.0px; text-align: left" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 44%; padding-bottom: 2.0px; padding-left: 0.0px; text-align: left" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 3%; padding-bottom: 2.0px; padding-left: 0.0px; text-align: left" valign="top">
          By:
        </td>
        <td style="border-bottom-style: solid; padding-left: 0.0px; text-align: left; border-bottom-color: black; border-bottom-width: 1.0pt" colspan="2" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            /s/ Dennis Bourgeault
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td style="width: 3%; padding-left: 0.0px; text-align: left" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 5%; padding-left: 0.0px; text-align: left" valign="top">
          Name:
        </td>
        <td style="width: 42%; padding-left: 0.0px; text-align: left" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Dennis Bourgeault
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%; padding-left: 0.0px; text-align: left" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 44%; padding-left: 0.0px; text-align: left" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 3%">

        </td>
        <td style="width: 5%; padding-left: 0.0px; text-align: left" valign="top">
          Title:
        </td>
        <td style="width: 42%; padding-left: 0.0px; text-align: left" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Chief Financial Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">

    </p>
    <div style="width: 100%; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="font-size: 10pt; text-align: center; font-family: Times New Roman">
          2
        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <b>EXHIBIT&#160;INDEX</b>
    </p>
<div style="text-align:left">
    <table style="width: 100%; font-size: 10pt; font-family: Times New Roman; margin-bottom: 10.0px" cellspacing="0">
      <tr>
        <td style="width: 7%; padding-bottom: 2.0px; padding-left: 0.0px; text-align: left" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <u><b>Exhibit</b></u>
          </p>
        </td>
        <td style="width: 5%; padding-bottom: 2.0px; padding-left: 0.0px; text-align: left" valign="bottom">
          &#160;
        </td>
        <td style="width: 88%; border-bottom-style: solid; padding-left: 0.0px; text-align: left; border-bottom-color: black; border-bottom-width: 1.0pt" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Description of Exhibit</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 7%">

        </td>
        <td style="width: 5%">

        </td>
        <td style="width: 88%; padding-left: 0.0px; text-align: left" valign="top">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 7%; padding-right: 0.0px; padding-left: 0.0px; white-space: nowrap; text-align: left" valign="top">
          99.1
        </td>
        <td style="width: 5%">

        </td>
        <td style="width: 88%; padding-left: 0.0px; text-align: left" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Aurinia Reports Second Quarter 2016 Financial Results and
            Operational Highlights
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>
      Exhibit 99.1 included with this report on Form 6-K is hereby
      incorporated by reference as exhibits to the Registration Statement on
      Form F-10 of Aurinia Pharmaceuticals Inc. (File No. 333-206994), as
      amended or supplemented.
    </p>
    <p>

    </p>
    <p>

    </p>
    <p>

    </p>
    <p style="text-align: center">
      3
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51396686ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2016 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>Aurinia
      Reports Second Quarter 2016 Financial Results and Operational Highlights</b></font>
    </p>
    <p style="text-align: center">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>Completed
      private placement for gross proceeds of $7.08 million</b></font></i>
    </p>
    <p style="text-align: center">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>AURION
      results support the use of voclosporin for the treatment of lupus
      nephritis</b></font></i>
    </p>
    <p style="text-align: center">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>AURA
      topline primary endpoint results imminent</b></font></i>
    </p>
    <p>
      VICTORIA, British Columbia--(BUSINESS WIRE)--August 5, 2016--Aurinia
      Pharmaceuticals Inc. (NASDAQ:AUPH-TSX:AUP) (&#8220;Aurinia&#8221; or the &#8220;Company&#8221;)
      has released its financial results for the second quarter ended June 30,
      2016. Amounts, unless specified otherwise, are expressed in U.S. dollars.
    </p>
    <p>
      The Aurinia team is focused on preparations for the AURA primary end
      point data release expected prior to the end of August, 2016, and
      initiation of the Phase 3 program in 2017. The Company is making the
      necessary investments now to ensure the team has the tools to deliver
      future success. The remainder of the year will also see further data
      releases from the AURION study including additional 24 week data points.
    </p>
    <p>
      The Company is also in the process of completing assessments of key
      markets in the Americas, Europe and Asia. The Company will share more on
      these developments during future investor presentations.
    </p>
    <p>
      &#8220;We are fast approaching a pivotal event for Aurinia with primary
      endpoint data from the AURA trial expected very soon. The Aurinia team
      is excited to have reached this stage in the development of voclosporin
      for lupus nephritis. We plan to continue to execute on initiatives to
      maximize shareholder value and help bring a desperately needed therapy
      to market for patients suffering from this disease,&#8221; said Charlie
      Rowland, CEO of Aurinia Pharmaceuticals Inc.
    </p>
    <p>
      <b>Operational and Corporate Developments</b>
    </p>
    <p>
      <b>AURA Phase 2b Clinical Trial Update</b>
    </p>
    <p>
      On January 19, 2016, the Company announced completion of patient
      enrollment of its AURA Phase 2b clinical trial at 265 patients (the
      target number of patients was 258).
    </p>
    <p>
      Un-blinding and disclosure of the primary trial data is scheduled within
      approximately one month of the last enrolled patient completing 24 weeks
      of active treatment. Therefore, the Company expects that the primary
      end-point results of the AURA trial will be released prior to the end of
      August, 2016.
    </p>
    <p>
      <b>AURION Study Update</b>
    </p>
    <p>
      On June 28, 2016 the Company announced that it completed an analysis of
      the first 7 patients to complete 24 weeks in its open-label AURION (<u>A</u>urinia
      early <u>U</u>rinary protein <u>R</u>educt<u>ion</u> Predicts Response)
      study. At 24 weeks 57% (4/7) of patients continued to be in complete
      remission as measured by a urinary protein creatinine ratio of &#8804;
      0.5mg/mg, eGFR within 20% of baseline and concomitant steroid dose of
      less than 5mg/day. Among these seven AURION patients there was a 54%
      mean reduction in proteinuria at 24 weeks compared to pre-treatment
      levels along with consistent improvements in C3, C4 and anti-DS DNA.
      Renal function as measured by eGFR remained stable and no new safety
      signals were observed.
    </p>
    <div style="width: 100%; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>Private Placement Financing</b>
    </p>
    <p>
      On June 22, 2016 the Company<i> </i>completed a private placement of 3
      million units of the Company at US$2.36 per unit for total gross
      proceeds of US$7.08 million. Each unit consisted of one common share of
      the Company and a 0.35 of one common share purchase warrant exercisable
      for a period of two years from the date of issuance at an exercise price
      of US$2.77.
    </p>
    <p>
      <b>At the Market (ATM) Facility</b>
    </p>
    <p>
      On July 22, 2016 the Company<b> </b>entered into a Controlled Equity
      Offering Sales Agreement with Cantor Fitzgerald &amp; Co. (&#8220;Cantor
      Fitzgerald&#8221;) pursuant to which the Company may from time to time sell,
      through at-the-market (&#8220;ATM&#8221;) offerings with Cantor Fitzgerald acting as
      sales agent, such common shares as would have an aggregate offer price
      of up to US$10 million.
    </p>
    <p>
      <b>The Company expects the following milestones and events in the second
      half of 2016:</b>
    </p>
    <ul>
      <li style="margin-bottom: 10.0px">
        AURA-LV 24 week primary end point data release &#8211; prior to the end of
        August 2016
      </li>
      <li style="margin-bottom: 10.0px">
        AURION 10 patients to 24 weeks &#8211; Q3/2016
      </li>
      <li style="margin-bottom: 10.0px">
        Investor Day &#8211; September 2016
      </li>
      <li style="margin-bottom: 10.0px">
        End of Phase 2 meeting with FDA&#8211; Q4/2016
      </li>
      <li style="margin-bottom: 10.0px">
        Scientific meetings: ACR &amp; ASN
      </li>
    </ul>
    <p>
      <b>Financial Results for the Second Quarter Ended June 30, 2016</b>
    </p>
    <p>
      The Company had cash, cash equivalents and short term investments of
      $12.1 million at June 30, 2016 compared to $10.5 million at March 31,
      2016 and $15.8 million at December 31, 2015. Net cash used in operating
      activities was $5.0 million for the second quarter ended June 30, 2016.
      The Company generated $6.6 million from financing activities during the
      quarter as a result of completing the private placement on June 22, 2016.
    </p>
    <p>
      For the second quarter ended June 30, 2016, the Company reported a
      consolidated net loss of $3.3 million or $0.10 per common share, as
      compared to a consolidated net loss of $733,000 or $0.02 per common
      share for the same period in 2015. The increase in the reported
      consolidated net loss was primarily attributable to a reduction in the
      non-cash gain on the quarterly fair value revaluation of the derivative
      warrant liability of $4.0 million offset to a lesser degree by a
      reduction in research and development expenses of $1.9 million in the
      second quarter ended June 30, 2016 compared to the same period in 2015.
    </p>
    <p>
      For the six months ended June 30, 2016, the consolidated net loss was
      $7.5 million or $0.23 per common share compared to a consolidated net
      loss of $9.3 million or $0.29 per common share for the comparable period
      in 2015. The lower consolidated net loss reflected a decrease in
      research and development expenses of $1.9 million for the 2016 period
      compared to the same period in 2015.
    </p>
    <p>
      Research and development expenses decreased to $2.4 million for the
      three months ended June 30, 2016, compared to $4.3 million for the three
      months ended June 30, 2015 as the costs related to the active treatment
      phase of the AURA trial have decreased as patients complete the trial.
      The Company incurred net research and development expenditures of $5.7
      million for the six months ended June 30, 2015, as compared to $7.6
      million for the same period in 2015.
    </p>
    <p>
      Corporate, administration and business development expenses increased to
      $1.8 million for the three months ended June 30, 2016, compared to $1.4
      million for the same period in 2015. The Company incurred corporate,
      administration and business development expenses of $3.0 million for the
      six months ended June 30, 2016 compared to $3.3 million for the same
      period in 2015.
    </p>
    <p>
      The unaudited interim condensed consolidated financial statements and
      the MD&amp;A for the second quarter ended June 30, 2016 are accessible on
      Aurinia's website at <u>www.auriniapharma.com</u> or on SEDAR at <u>www.sedar.com</u>
      or on EDGAR at <u>www.sec.gov/edgar</u>.
    </p>
    <p>
      <i><b>About Aurinia:</b></i>
    </p>
    <p>
      Aurinia is a clinical stage pharmaceutical company focused on the global
      nephrology market. The fully-enrolled AURA clinical trial is evaluating
      the efficacy of its lead drug, voclosporin, as a treatment for active
      LN. LN is an inflammation of the kidneys, that if inadequately treated
      can lead to end-stage renal disease, making LN a serious and potentially
      life-threatening condition.
    </p>
    <div style="width: 100%; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      Voclosporin is a novel and potentially best-in-class calcineurin
      inhibitor (&#8220;CNI&#8221;) with extensive clinical data in over 2,000 patients in
      other indications. Voclosporin is made by a modification of a single
      amino acid of the cyclosporine molecule (a CNI approved for use in
      transplant patients since 1983). This modification results in a more
      predictable pharmacokinetic and pharmacodynamic relationship, an
      increase in potency vs. cyclosporine, an altered metabolic profile, and
      potential for flat dosing.
    </p>
    <p>
      <i><b>About AURA:</b></i>
    </p>
    <p>
      The AURA trial is an adequate and well-controlled clinical trial that
      enrolled 265 patients and is being conducted in over 20 countries
      worldwide. This trial will compare the efficacy of voclosporin against
      placebo in achieving remission in patients with active lupus nephritis.
      The AURA trial designed to demonstrate that voclosporin can induce a
      rapid and sustained reduction of proteinuria in the presence of
      extremely low steroid exposure. It will compare two dosage groups of
      voclosporin (23.7mg and 39.5mg) compared to placebo, with all patients
      receiving mycophenolate mofetil (MMF) and oral corticosteroids as
      background therapy. There will be a primary analysis to determine
      complete remission at week 24 (confirmed at 26 weeks) and various
      secondary analyses at week 48 which include biomarkers and markers of
      non-renal SLE.
    </p>
    <p>
      <i><b>About AURION:</b></i>
    </p>
    <p>
      The AURION study is an open label, exploratory study being conducted at
      two sites in Malaysia to assess the short term predictors of response
      using voclosporin (23.7mg) in combination with mycophenolate mofetil and
      oral corticosteroids in patients with active lupus nephritis. This study
      will examine biomarkers of disease activity at 8 weeks and their ability
      to predict response at 24 and 48 weeks.
    </p>
    <p>
      <i><b>Forward-Looking Statements</b></i>
    </p>
    <p>
      A statement is forward-looking when it uses what the Company knows and
      expects today to make a statement about the future. Forward-looking
      statements may include words such as &#8220;<i>anticipate&#8221;, &#8220;believe&#8221;,
      &#8220;intend&#8221;, &#8220;expect&#8221;, &#8220;goal&#8221;, &#8220;may&#8221;, &#8220;outlook&#8221;, &#8220;plan&#8221;, &#8220;seek&#8221;, &#8220;should&#8221;,
      &#8220;strive&#8221;, &#8220;target&#8221;, &#8220;could&#8221;, &#8220;continue&#8221;, &#8220;potential&#8221; </i>and
      <i>&#8220;estimated&#8221;</i>, or the negative of such terms or
      comparable terminology. You should not place undue reliance on
      forward-looking statements, particularly those concerning anticipated
      events relating to the development, clinical trials, regulatory
      approval, and marketing of the Company&#8217;s product and the timing or
      magnitude of those events, as they are inherently risky and uncertain.
    </p>
    <p>
      Securities laws encourage companies to disclose forward-looking
      information so that investors can get a better understanding of the
      Company&#8217;s future prospects and make informed investment decisions. In
      this press release, these statements may include, without limitation:
    </p>
    <ul>
      <li style="margin-bottom: 10.0px">
        plans to fund the Company&#8217;s operations;
      </li>
      <li style="margin-bottom: 10.0px">
        summary statements relating to results of the past voclosporin trials
        or plans to advance the development of voclosporin;
      </li>
      <li style="margin-bottom: 10.0px">
        the timing of the release of the primary end-point results of AURA ;
      </li>
      <li style="margin-bottom: 10.0px">
        the timing of the analysis and review of the AURA data with the FDA;
      </li>
      <li style="margin-bottom: 10.0px">
        the timing of commencement and completion of clinical trials;
      </li>
      <li style="margin-bottom: 10.0px">
        voclosporin being a best-in-class calcineurin inhibitor;
      </li>
      <li style="margin-bottom: 10.0px">
        the Company&#8217;s anticipated future financial position, future revenues
        and projected costs;
      </li>
      <li style="margin-bottom: 10.0px">
        the Company&#8217;s intention to raise additional funds in the next 12
        months;
      </li>
      <li style="margin-bottom: 10.0px">
        the timing of the Company&#8217;s anticipated milestones for 2016; and
      </li>
      <li style="margin-bottom: 10.0px">
        plans and objectives of management.
      </li>
    </ul>
    <p>
      Such statements reflect the Company&#8217;s current views with respect to
      future events and are subject to risks and uncertainties and are
      necessarily based on a number of estimates and assumptions that, while
      considered reasonable by the Company, as at the date of such statements,
      are inherently subject to significant business, economic, competitive,
      political, scientific and social uncertainties and contingencies, many
      of which, with respect to future events, are subject to change. The
      factors and assumptions used by the Company to develop such
      forward-looking statements include, but are not limited to: the
      assumption that the Company will be able to reach agreements with
      regulatory agencies on executable development programs; the assumption
      that recruitment to clinical trials will occur as projected; the
      assumption that the Company will successfully complete its clinical
      programs on a timely basis, including the AURA clinical trial currently
      in progress, to enable the Company to proceed to conduct future required
      LN clinical trials and meet regulatory requirements for approval of
      marketing authorization applications and new drug approvals; the
      assumption the regulatory requirements will be maintained; the
      assumption that the Company will be able to manufacture and secure a
      sufficient supply of voclosporin on a timely basis to successfully
      complete the development and commercialization of voclosporin; the
      assumption that market data and reports reviewed by the Company are
      accurate; the assumptions relating to the availability of capital on
      terms that are favourable to the Company; the assumption that the
      Company will be able to attract and retain skilled staff; the assumption
      that general business and economic conditions will be maintained, and
      the assumptions relating to the feasibility of future clinical trials.
    </p>
    <div style="width: 100%; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      It is important to know that:
    </p>
    <ul>
      <li style="margin-bottom: 10.0px">
        Actual results could be materially different from what the Company
        expects if known or unknown risks affect its business, or if the
        Company&#8217;s estimates or assumptions turn out to be inaccurate. As a
        result, the Company cannot guarantee that any forward-looking
        statement will materialize and, accordingly, you are cautioned not to
        place undue reliance on these forward-looking statements.
      </li>
      <li style="margin-bottom: 10.0px">
        Forward-looking statements do not take into account the effect that
        transactions or non-recurring or other special items announced or
        occurring after the statements are made may have on the Company&#8217;s
        business. For example, they do not include the effect of mergers,
        acquisitions, other business combinations or transactions,
        dispositions, sales of assets, asset write-downs or other charges
        announced or occurring after the forward-looking statements are made.
        The financial impact of such transactions and non-recurring and other
        special items can be complex and necessarily depends on the facts
        particular to each of them. Accordingly, the expected impact cannot be
        meaningfully described in the abstract or presented in the same manner
        as known risks affecting the Company&#8217;s business.
      </li>
      <li style="margin-bottom: 10.0px">
        The Company disclaims any intention and assumes no obligation to
        update any forward-looking statements even if new information becomes
        available, as a result of future events, new information, or for any
        other reason except as required by law.
      </li>
    </ul>
    <p>
      Such forward-looking statements involve known and unknown risks,
      uncertainties, and other factors that may cause the Company&#8217;s actual
      results, performance, or achievements to differ materially from any
      further results, performance or achievements expressed or implied by
      such forward-looking statements. Important factors that could cause such
      differences include, among other things, the following:
    </p>
    <ul>
      <li style="margin-bottom: 10.0px">
        the need for additional capital to fund the Company&#8217;s development
        programs and the effect of capital market conditions and other factors
        on capital availability;
      </li>
      <li style="margin-bottom: 10.0px">
        difficulties, delays, or failures the Company may experience in the
        conduct of and reporting of results of its clinical trials for
        voclosporin, and in particular its current AURA clinical trial;
      </li>
      <li style="margin-bottom: 10.0px">
        difficulties, delays or failures in obtaining regulatory approvals for
        the initiation of clinical trials;
      </li>
      <li style="margin-bottom: 10.0px">
        difficulties the Company may experience in completing the development
        and commercialization of voclosporin;
      </li>
    </ul>
    <p>
      Although the Company believes that the expectations reflected in the
      forward-looking statements are reasonable, the Company cannot guarantee
      future results, levels of activity, performance or achievements. These
      forward-looking statements are made as of the date hereof.
    </p>
    <p>
      <i>We seek Safe Harbor</i>.
    </p>
    <p>

    </p>
    <p>
      CONTACT:<br>Aurinia Pharmaceuticals Inc.<br>Mr. Michael Martin,
      250-708-4272<br>Fax: 250-744-2498<br>Chief Operating Officer<br>mmartin@auriniapharma.com<br>or<br>Mr.
      Dennis Bourgeault, 780-643-2260<br>Fax: 780-484-4105<br>Chief Financial
      Officer<br><u>dbourgeault@auriniapharma.com</u>
    </p>
    <p>

    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
